The Leading eBooks Store Online
for Kindle Fire, Apple, Android, Nook, Kobo, PC, Mac, Sony Reader...
Ankylosing spondylitis and Klebsiella
US$ 149.99
(+ tax)
Preview (read now)
Add to my own site
Give this ebook to a friend
Add to my wishlist
Author's page
Publisher's page
Devices
- iPad
- PC
- e-readers with Adobe Digital Editions installed
- Mac
See the full list
Available Devices
X
This book is available for the following devices:
- iPad
- Windows
- Mac
- Sony Reader
- Cool-er Reader
- Nook
- Kobo Reader
- iRiver Story
File Formats
Download: secure PDF.
You can also read this book online in eb20 format without having to download anything.
You can also read this book online in eb20 format without having to download anything.
Permissions
Printing
Copy/Paste
Read Aloud
Printing
Copy/Paste
Read Aloud
more
"Ankylosing spondylitis and Klebsiella" is a comprehensive and informative text on the cause of Ankylosing spondylitis. Ankylosing spondylitis (AS) is a condition which affects 20 million people worldwide and is likely caused or initiated by a bowel infection from Klebsiella bacteria. When a patient is infected by Klebsiella bacteria, his or her immune system will make antibodies against all the antigens or molecules found in the microbe. Because some of the bacterial antigens resemble self tissues, the anti-bacterial antibodies will attack not only the bacteria but also the self tissues such as the joints and the cells having the same HLA molecules, which is how the disease AS starts. This is the concept of molecular similarity or "molecular mimicry" which previously has been found to work in two other autoimmune diseases; rheumatic fever and rheumatoid arthritis. The first paper on this subject was published in 1976 and since then over 100 papers on rheumatological topics have been published, from Prof Ebringer's group, at the Division of Life Sciences, King's College in London, UK.The relevant information from these papers is extracted and presented in this book format making it accessible to health professionals, research institutions, pharmaceutical companies and universities and the general public.
less
